Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20231107025
- Term of Validity
- 10 November 2023 - 9 November 2024
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistanceResearch and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The company is a seed-stage deep-tech startup based in the United Kingdom that is developing a neuromorphic computing technology to generate high-dimensional data on a molecule’s underlying biophysics, enabling rapid characterization 20x cheaper and 10x faster than the state-of-the-art. The company already has early market traction (10+ successful pilots) and is looking to further expand its impact to potential customer/partners .
- Full Description
-
The company is a seed-stage startup based in the United Kingdon that is building a technology platform for molecular characterization. The primary innovation of the company is a hardware that when exposed to any external stimulus, say an antibody drug candidate, generates a unique digital fingerprint that embeds the physical-chemical properties for the sample. These fingerprints are assessed to rapidly screen and classify candidates for desired properties. For example, screening antibody candidates for desired developability properties or even plant proteins for a real-like meatless chicken .
The company is focussed on developing their product over the next 6-12 months culminating with a limited launch with selected partners. We are seeking international partners to expose our technology to a variety of use cases and materials in the bioengineered and precision fermentation sector. Through these partnerships we would
1) validate our understanding of their critical pain points and the suitability of Apoha’s solution and
2) provide requirements and samples, jointly review Apoha’s results and offer feedback on the utility of those results.
Currently, the tech has been validated across a range of use cases - from antibody developability assessment to lipid nanoparticle excipient classification. Their goal is to deploy edge devices to empower labs around the world, but as of now operates through a service-for-fee model and is actively looking for partners who are screening antibodies, lipids, proteins, and peptides and who would benefit from a multi-parametric assessment at 10x speed and 20x efficiency. - Advantages and Innovations
- Using the company’s tech, protein/lipid engineers and formulation scientist can design any compound or material for the desired target function. This is a single-experiment multi-parametric assessment that gives you a holistic picture of a material’s characteristics, which by using you can compare any two materials based on underlying biophysics. Simply put, they are doing to materials what generative AI has done to natural language processing applications, and there is no other product on the market with this capability .
- Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 17: Partnerships to achieve the GoalGoal 12: Responsible Consumption and ProductionGoal 3: Good Health and Well-beingGoal 9: Industry, Innovation and Infrastructure
Partner Sought
- Expected Role of a Partner
-
The company is seeking partners across multiple use-cases in the biologics sector, which includes, but is not limited to companies that manufacture or use therapeutic antibodies, nucleic acids, lipid nanoparticles, biosimilars, and/or peptides . Our objective is to engage with ‘early-adopter’ partners in the biologics sector to test our technology. An ideal partner would 1) validate our understanding of their critical pain points and the suitability of Apoha’s solution 2) provide requirements and samples, jointly review Apoha’s results and offer feedback on the utility of those results.
The company is operating through a service-for-fee model right now, where the partner would be required to supply samples for the company to test, jointly review the data insights, and offer feedback on the usability of those insights.
The goal is to expose the technology to a variety of use cases and materials, and in the process also help our partners make better decisions faster. - Type and Size of Partner
- SME 11-49
- Type of partnership
- Commercial agreement with technical assistanceResearch and development cooperation agreement
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 06004 - Micro- and Nanotechnology related to Biological sciences06001001 - Biostatistics, Epidemiology006001007 - Diseases06001006 - Human vaccines06002001 - Biochemistry / Biophysics
- Market keywords
- 02007012 - Medical/health software04007 - Enzymology/Protein Engineering/Fermentation04006 - Cellular and Molecular Biology04010 - Microbiology
- Targeted countries
- All countries